A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Custirsen (Primary) ; Cabazitaxel; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms AFFINITY
- Sponsors OncoGenex Pharmaceuticals
- 11 Oct 2016 Results assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Status changed from active, no longer recruiting to completed.
- 19 Sep 2016 This trail was completed in Czech Republic (end date: 15-07-2016), according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History